BioSpace News Archive

Drug Development

Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study

Debiopharm, a Swiss biopharmaceutical company, announced the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors.

December 16, 2021
·
4 min read
c-LEcta Continues Its Growth in 2021 and Sees Itself Excellently Positioned for the Future With the ENESYZ Technology Platform

c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, continued its growth in 2021.

December 16, 2021
·
4 min read
Synerkine Pharma Raises EUR 3.5 Million in an Extended Series A Financing

Synerkine Pharma B.V. announced that it has added EUR 3.5 million to its Series A funding.

December 16, 2021
·
2 min read
Antengene and XtalPi Announce AI-Driven R&D Collaboration

Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.

December 16, 2021
·
4 min read
Business

Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases

Metrion Biosciences Limited and Bioqube Ventures announced that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.

December 16, 2021
·
2 min read
Deals

ZOLL Announces Closing of Acquisition of Itamar Medical

ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd., a medical device and digital health company that provides at-home testing for sleep apnea.

December 16, 2021
·
7 min read
Drug Development

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with macular edema due to retinal vein occlusion.

December 16, 2021
·
11 min read
Bio NC

G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will hire and deploy an additional 20 salespeople, bringing the total number of oncology sales representatives to 34.

December 16, 2021
·
5 min read
Biotech Beach

SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro

SAB Biotherapeutics announced data demonstrating that SAB-185, the company’s therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model.

December 16, 2021
·
7 min read
Deals

Bionomics Limited Announces Pricing of Initial Public Offering in the United States

Bionomics Limited, a clinical-stage biopharmaceutical company, announced the pricing of its initial public offering in the United States of 1,622,000 American Depositary Shares, each representing 180 ordinary shares of Bionomics, at an initial public offering price of US$12.35 per ADS.

December 16, 2021
·
4 min read